Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
CAMBRIDGE, Mass., April 27, 2017 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, May 4, 2017 at 9:00 a.m. ET to discuss financial results for the first quarter 2017. Genocea management will also provide an update on the Company's recent progress and upcoming milestones.
Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 13446635. To join the live webcast, please visit the investor relations section of the Genocea website at http://ir.genocea.com.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.
About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea used ATLAS to identify the antigens in its lead clinical candidate, GEN-003, an investigational immunotherapy to treat genital herpes, and is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines and to identify T cell response signatures of cancer patients treated with checkpoint blockade therapies to potentially improve clinical practice. Genocea expects GEN-003 to be ready to begin Phase 3 development and to file an IND for its neoantigen cancer vaccine candidate GEN-009 by the end of 2017. For more information, please visit the company's website at www.genocea.com.
For media: Jennifer LaVin O: 617-715-6687 [email protected] For investors: Jonathan Poole O: 617-876-8191 [email protected]
